Literature DB >> 24478427

Specific sequence of a Beta turn in human la protein may contribute to species specificity of hepatitis C virus.

Anuj Kumar1, Asit Kumar Manna, Upasana Ray, Ranajoy Mullick, Gautam Basu, Saumitra Das, Siddhartha Roy.   

Abstract

UNLABELLED: Human La protein is known to be an essential host factor for translation and replication of hepatitis C virus (HCV) RNA. Previously, we have demonstrated that residues responsible for interaction of human La protein with the HCV internal ribosomal entry site (IRES) around the initiator AUG within stem-loop IV form a β-turn in the RNA recognition motif (RRM) structure. In this study, sequence alignment and mutagenesis suggest that the HCV RNA-interacting β-turn is conserved only in humans and chimpanzees, the species primarily known to be infected by HCV. A 7-mer peptide corresponding to the HCV RNA-interacting region of human La inhibits HCV translation, whereas another peptide corresponding to the mouse La sequence was unable to do so. Furthermore, IRES-mediated translation was found to be significantly high in the presence of recombinant human La protein in vitro in rabbit reticulocyte lysate. We observed enhanced replication with HCV subgenomic and full-length replicons upon overexpression of either human La protein or a chimeric mouse La protein harboring a human La β-turn sequence in mouse cells. Taken together, our results raise the possibility of creating an immunocompetent HCV mouse model using human-specific cell entry factors and a humanized form of La protein. IMPORTANCE: Hepatitis C virus is known to infect only humans and chimpanzees under natural conditions. This has prevented the development of a small-animal model, which is important for development of new antiviral drugs. Although a number of human-specific proteins are responsible for this species selectivity and some of these proteins--mostly entry factors--have been identified, full multiplication of the virus in mouse cells is still not possible. In this study, we show that a turn in the human La protein that is responsible for the interaction with the viral RNA is highly specific for the human sequence. Replacement of the corresponding mouse sequence with the human sequence allows the mouse La to behave like its human counterpart and support viral growth in the mouse cell efficiently. This observation, in combination with previously identified cell entry factors, should open up the possibility of creating a mouse model of hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24478427      PMCID: PMC3993764          DOI: 10.1128/JVI.00049-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  New horizons for studying human hepatotropic infections.

Authors:  Ype P de Jong; Charles M Rice; Alexander Ploss
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

Review 2.  Animal models for the study of hepatitis C virus infection and related liver disease.

Authors:  Jens Bukh
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

3.  Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line.

Authors:  Sibylle Haid; Marc P Windisch; Ralf Bartenschlager; Thomas Pietschmann
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

4.  Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122.

Authors:  Liang-Tzung Lin; Ryan S Noyce; Tram N Q Pham; Joyce A Wilson; Gary R Sisson; Thomas I Michalak; Karen L Mossman; Christopher D Richardson
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

5.  Mouse hepatic cells support assembly of infectious hepatitis C virus particles.

Authors:  Gang Long; Marie-Sophie Hiet; Marc P Windisch; Ji-Young Lee; Volker Lohmann; Ralf Bartenschlager
Journal:  Gastroenterology       Date:  2011-06-13       Impact factor: 22.682

6.  Modulation of hepatitis C virus replication by iron and hepcidin in Huh7 hepatocytes.

Authors:  Giody Bartolomei; Recep Emrah Cevik; Alessandro Marcello
Journal:  J Gen Virol       Date:  2011-05-18       Impact factor: 3.891

7.  Structural determinant of human La protein critical for internal initiation of translation of hepatitis C virus RNA.

Authors:  Tanmoy Mondal; Upasana Ray; Asit Kumar Manna; Romi Gupta; Siddhartha Roy; Saumitra Das
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

8.  Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV).

Authors:  Hussein Hassan Aly; Hiroyuki Oshiumi; Hiroaki Shime; Misako Matsumoto; Taka Wakita; Kunitada Shimotohno; Tsukasa Seya
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

9.  A genetically humanized mouse model for hepatitis C virus infection.

Authors:  Marcus Dorner; Joshua A Horwitz; Justin B Robbins; Walter T Barry; Qian Feng; Kathy Mu; Christopher T Jones; John W Schoggins; Maria Teresa Catanese; Dennis R Burton; Mansun Law; Charles M Rice; Alexander Ploss
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

10.  Human occludin is a hepatitis C virus entry factor required for infection of mouse cells.

Authors:  Alexander Ploss; Matthew J Evans; Valeriya A Gaysinskaya; Maryline Panis; Hana You; Ype P de Jong; Charles M Rice
Journal:  Nature       Date:  2009-01-28       Impact factor: 49.962

View more
  2 in total

1.  Immunocompetent mouse models to evaluate intrahepatic T cell responses to HCV vaccines.

Authors:  Wenbo Yu; Branka Grubor-Bauk; Ranajoy Mullick; Saumitra Das; Eric J Gowans
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients.

Authors:  Pilar Brito-Zerón; Hoda Gheitasi; Soledad Retamozo; Albert Bové; María Londoño; Jose-Maria Sánchez-Tapias; Miguel Caballero; Belchin Kostov; Xavier Forns; Srini V Kaveri; Manuel Ramos-Casals
Journal:  Arthritis Res Ther       Date:  2015-09-10       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.